Semisynthesis of an Anticancer DPAGT1 Inhibitor from a Muraymycin Biosynthetic Intermediate by Mitachi, Katsuhiko et al.
 
S1 
 
Supporting Information 
 
for 
A Semi-Synthesis of an Anticancer DPAGT1 Inhibitor from a Muraymycin 
Biosynthetic Intermediate 
 
Katsuhiko Mitachi,a Shou M. Kurosu,a Shakiba Eslamimehr,a Maddie R. Lemieux,a 
Yoshimasa Ishizaki,b William M. Clemons Jr.,c and Michio Kurosu*a 
a Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee 
Health Science Center, 881 Madison Avenue, Memphis, TN 38163, USA 
b Laboratory of Microbiology, Institute of Microbial Chemistry (BIKAKEN), Tokyo, 3-
14-23, Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan 
c Division of Chemistry and Chemical Engineering, California Institute of Technology, 
1200 E. California Blvd. Pasadena, CA 91125, USA 
mkurosu@uthsc.edu 
 
 
Table of Contents 
 
 
Table of contents--------------------------------------------------------------------------S1 
 
General -------------------------------------------------------------------------------------S2 
 
Experimental -------------------------------------------------------------------------------S3-S18 
 
Copies of 1H and 13C NMR spectra----------------------------------------------------S19-S43 
 
 
 
 
 
 
S2 
 
General 
 
All chemicals were purchased from commercial sources and used without further 
puriﬁcation unless otherwise noted. THF, CH2Cl2, and DMF were purified via Innovative 
Technology's Pure-Solve System. All reactions were performed under an Argon 
atmosphere. All stirring was performed with an internal magnetic stirrer. Reactions were 
monitored by TLC using 0.25 mm coated commercial silica gel plates (EMD, Silica Gel 
60F254). TLC spots were visualized by UV light at 254 nm, or developed with ceric 
ammonium molybdate or anisaldehyde or copper sulfate or ninhydrin solutions by 
heating on a hot plate. Reactions were also monitored by using SHIMADZU LCMS-2020 
with solvents: A: 0.1% formic acid in water, B: acetonitrile. Flash chromatography was 
performed with SiliCycle silica gel (Purasil 60 Å, 230-400 Mesh). Proton magnetic 
resonance (1H-NMR) spectral data were recorded on 400, and 500 MHz instruments. 
Carbon magnetic resonance (13C-NMR) spectral data were recorded on 100 and 125 MHz 
instruments. For all NMR spectra, chemical shifts (δH, δC) were quoted in parts per 
million (ppm), and J values were quoted in Hz. 1H and 13C NMR spectra were calibrated 
with residual undeuterated solvent (CDCl3: δH = 7.26 ppm, δC = 77.16 ppm; CD3CN: δH 
= 1.94 ppm, δC = 1.32ppm; CD3OD: δH =3.31 ppm, δC =49.00 ppm;  DMSO-d6: δH = 
2.50 ppm, δC = 39.52 ppm; D2O: δH = 4.79 ppm) as an internal reference. The following 
abbreviations were used to designate the multiplicities: s = singlet, d = doublet, dd = 
double doublets, t = triplet, q = quartet, quin = quintet, hept = heptet, m = multiplet, br = 
broad. Infrared (IR) spectra were recorded on a Perkin-Elmer FT1600 spectrometer. 
HPLC analyses were performed with a Shimadzu LC-20AD HPLC system. HR-MS data 
were obtained from a Waters Synapt G2-Si (ion mobility mass spectrometer with 
nanoelectrospray ionization). 
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Isolation of muraymycin biosynthetic intermediate 3: 
 
Streptomyces sp. NRRL 30471 (acquired from USDA) was cultured on a yeast malt 
extract agar plate (containing dextrose: 5 g, peptone: 2.5 g, malt extract: 1.5 g, yeast 
extract: 1.5 g, and agar: 10 g in water, 500 mL) at 27 oC for 4 days. A single colony was 
isolated, and cultured in yeast malt extract (containing dextrose 5 g, peptone 2.5 g, malt 
extract 1.5 g, and yeast extract 1.5 g in water, 500 mL) in a 250 mL Erlenmeyer flasks at 
27 oC for 4 days to obtain a seed culture for fermentation. 
 
 
 
An aliquot of the seed culture obtained above was inoculated into flasks (500 mL), each 
containing (glucose: 10 g, starch: 5 g, yeast extract: 4.5 g, peptone: 2.5 g, meat extract: 
2.5 g, NaCl: 2.5 g, CaCO3: 1.5 g, CB-442 (NOF Co., Ltd. Japan): (0.13% in water, 376 
uL), pH 7.4). The fermentation (500 mL x3) was continued for 7 days at 23 °C on a 
rotary shaker (175 rpm). All culture flasks were combined and centrifuged at 4,700g for 
20 min to separate the mycelium and water phase. The mycelial-cake portion was 
suspended in methanol (500 mL) and kept at -20 oC for 0.5 h, and the cells were crushed 
by sonication (5 s on 2 s off for 5 min x2) at ice-water temperature. The organic phase 
was separated by centrifugation (4,700g for 5 min) and the precipitates were washed with 
MeOH. The combined MeOH extracts were evaporated to afford the brown solid (2.0 g 
wet). The water phase was adjusted ~pH 6.0 with 1 N HCl, and passed through a column 
of activated carbon. The column was washed with water (600 mL), 60% aq acetone (600 
mL), and eluted with 0.3% NH4OH in 60% aq acetone (500 - 1000 mL). The eluate was 
evaporated to provide the brown solid (1.5 g). The products obtained from intracellular 
and extracellular material were combined (~3.5 g) and purified by SiO2 
(nBuOH:EtOH:CHCl3:NH4OH = 4:7:6:2 to 4:7:2:2 to 4:7:2:7); the crude products were 
separated into two groups (upper and lower spots), and the base-line materials were 
removed. The both fractions were separately dissolved in MeOH and the precipitates 
were filtered off. The MeOH extracts were concentrated and purified by Sephadex G25 
(GH Healthcare) with MeOH; the first fractions (UV and nihydrin positive) were 
collected (350 mg). The obtained materials were absorbed on Dowex-22 (ammonium 
hydoxide-resin) in MeOH and washed with MeOH, and eluted with 0.1 N HCl in MeOH 
(1/10). The isolated materials were separated by reverse-HPLC (00G-4253-No, Luna 10 
m C18 100 Å, 250 x10 mm, 30% MeOH (15 min) to 60% MeOH (30 min) to 100% 
MeOH (10 min) flow rate 3 mL/min). The peak corresponding to the muraymycin 
biosynthetic intermediate 3 was collected. The purified 3 was identical to a synthetic 
sample in HPLC retention time. Due to low isolation yield of 3 under the current 
fermentation condition with the Streptomyces sp. NRRL 30471 strain, the reactions 
summarized in Table 1 were performed with synthetic 3.1 
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HPLC analysis of 3 contained eluent. 
 
 
 
HPLC analysis of synthetic 3. 
 
 
Figure S1: HPLC chromatograms of 3 
 
 
Amide-formation of 3. 
 
O
NH2
HO
HO
O
N
NH
O
O
HO OH
O
H
NH2N
OH2N
O
N
CN
OHO
O
O
Me
Me
O
NH2
HO
HO
O
N
NH
O
O
HO OH
O
H
NH2N
OHO
3 4
5
NH4Cl, EDCI
NaHCO3
DMF-H2O
 
 
(2S,3S)-3-(((2S,3R,4S,5R)-5-(Aminomethyl)-3,4-dihydroxytetrahydrofuran-2-
yl)oxy)-2-((3-aminopropyl)amino)-3-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)propanamide (4). To a stirred solution 
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of 3  (32 mg, 0.06 mmol), NH4Cl (0.17 g, 3.17 mmol), NaHCO3 (80 mg, 0.95 mmol) and 
5 2 (72 mg, 0.32 mmol) in DMF/H2O (9:1, 0.60 mL) was added EDCI (61 mg, 0.32 
mmol). The reaction mixture was stirred for 8 h at rt, filtered and concentrated in vacuo. 
The crude mixture was purified by C18 reverse-phase HPLC [column: Luna® (100 Å, 10 
m, 250 x 10 mm), solvents: 5:95 MeOH:0.05 M NH4HCO3 in H2O, flow rate: 3.0 
mL/min, UV: 254 nm] to afford 4 (30 mg, 0.061 mmol, 95%, retention time: 6.7 min): 
TLC (n-butanol/ethanol/CHCl3/28% aq ammonia 4:7:2:7) Rf = 0.10; []22D +0.168 (c = 
0.26, methanol); IR (thin film) max = 3298 (br), 2923, 2852, 1677, 1632, 1464, 1405, 
1272, 1112, 1061 cm−1; 1H NMR (400 MHz, Deuterium Oxide) δ 7.70 (d, J = 8.1 Hz, 1H), 
5.84 (d, J = 8.0 Hz, 1H), 5.72 (d, J = 2.7 Hz, 1H), 5.18 (s, 1H), 4.37 (dd, J = 5.6, 2.8 Hz, 
1H), 4.26 (t, J = 6.5 Hz, 2H), 4.20 (dd, J = 7.5, 4.8 Hz, 1H), 4.13 – 4.06 (m, 3H), 3.94 – 
3.75 (m, 1H), 3.31 (d, J = 13.4 Hz, 1H), 3.12 – 3.06 (m, 1H), 3.01 (dt, J = 6.9, 3.4 Hz, 
2H), 2.95 – 2.83 (m, 1H), 2.83 – 2.68 (m, 1H), 1.93 – 1.80 (m, 2H); 13C NMR (101 MHz, 
D2O) δ 166.19, 163.11, 162.76, 151.29, 142.38, 108.44, 101.89, 91.71, 83.25, 78.45, 
74.44, 72.81, 71.54, 69.33, 62.08, 44.89, 42.07, 37.52; HRMS (ESI+) m/z calcd for 
C19H33N6O10 [M + H] 505.2258, found: 505.2272. 
 
 
 
Chemical synthesis of muraymycin biosynthetic intermediate 3. 
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(2R,3R,4R,5S)-2-(((tert-Butoxycarbonyl)amino)methyl)-5-(((1S)-1-((3aR,4R,6R,6aR)-
6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
4-yl)-2,3-dihydroxy-5-phenylpentyl)oxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (S1). The title compound was synthesized according 
to the reported procedure 1: TLC (hexanes/EtOAc 67:33) Rf = 0.30; []22D 0.210 (c = 1.62, 
CHCl3); IR (thin film) max = 3444 (br), 2941, 2866, 1741, 1719, 1675, 1600, 1556, 1457, 
1382, 1367, 1278, 1249, 1216, 1160, 1098, 1070, 1049, 1013, 998, 882, 867, 754, 681 
cm−1; 1H NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 8.4, 3.6 Hz, 1H), 7.31 (d, J = 2.0 Hz, 
2H), 7.30 – 7.27 (m, 2H), 7.25 – 7.14 (m, 6H), 6.85 (d, J = 3.4 Hz, 2H), 6.50 (d, J = 5.9 
Hz, 1H), 5.75 (dd, J = 17.6, 8.0 Hz, 1H), 5.63 (d, J = 22.1 Hz, 1H), 5.58 – 5.52 (m, 2H), 
5.48 (d, J = 9.7 Hz, 1H), 5.21 (q, J = 7.3, 6.2 Hz, 2H), 5.11 (d, J = 6.8 Hz, 1H), 5.01 (dd, 
J = 8.4, 4.7 Hz, 1H), 4.85 – 4.78 (m, 2H), 4.25 (d, J = 5.6 Hz, 1H), 4.16 (dt, J = 8.6, 4.4 
Hz, 1H), 4.03 (dd, J = 14.2, 5.1 Hz, 1H), 3.90 (d, J = 1.8 Hz, 1H), 3.78 (d, J = 1.8 Hz, 
4H), 3.77 – 3.71 (m, 4H), 3.69 – 3.62 (m, 2H), 3.39 – 3.22 (m, 2H), 2.97 – 2.86 (m, 2H), 
2.77 – 2.66 (m, 2H), 2.34 – 2.18 (m, 5H), 2.12 – 2.00 (m, 1H), 1.91 – 1.67 (m, 2H), 1.64 
– 1.51 (m, 4H), 1.42 (s, 6H), 1.35 (d, J = 3.9 Hz, 3H), 1.13 – 0.99 (m, 41H), 0.99 – 0.94 
(m, 6H), 0.86 (dtd, J = 9.1, 6.6, 2.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.85, 
170.74, 170.70, 170.70, 162.10, 162.09, 159.44, 159.44, 156.05, 150.59, 150.53, 141.92, 
141.89, 136.87, 136.84, 135.25, 135.09, 133.96, 133.77, 131.21, 131.17, 129.37, 129.32, 
128.43 (2C), 128.38 (2C), 126.22, 126.14, 125.81, 125.36, 125.26, 115.27, 114.97, 80.36, 
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80.34, 79.85, 79.67, 79.58, 74.64, 74.62, 74.60, 73.82, 73.77, 73.72, 70.31, 70.31, 59.94, 
59.90, 55.69, 46.13, 45.92, 44.72, 34.63, 34.50, 32.58, 32.57, 32.55, 32.54, 31.76, 29.69, 
29.03, 28.35, 27.28, 27.22, 26.88, 25.32, 25.25, 20.68, 18.04 (1C), 11.88 (3C), 11.86 (3C), 
11.43; HRMS (ESI+) m/z calcd for C79H120Cl4N3O19Si2 [M + H] 1610.6809, found: 
1610.6827. Data for polar diastereomer: TLC (hexanes/EtOAc 67:33) Rf = 0.20; []22D 
0.071 (c = 1.08, CHCl3); IR (thin film) max = 3413 (br), 2941, 2866, 1719, 1675, 1457, 
1367, 1278, 1248, 1219, 1160, 1099, 1070, 1049, 882, 772 cm−1; 1H NMR (400 MHz, 
CDCl3) δ 7.58 (d, J = 8.5 Hz, 1H), 7.31 – 7.29 (m, 2H), 7.28 (s, 2H), 7.24 – 7.11 (m, 6H), 
6.84 (d, J = 1.4 Hz, 2H), 6.51 (d, J = 6.6 Hz, 1H), 5.90 (dd, J = 6.3, 2.7 Hz, 1H), 5.84 (t, J 
= 8.2 Hz, 1H), 5.61 – 5.41 (m, 2H), 5.23 – 5.10 (m, 2H), 5.04 (t, J = 5.8 Hz, 2H), 4.86 – 
4.77 (m, 1H), 4.68 (ddd, J = 21.0, 6.3, 2.8 Hz, 1H), 4.57 (dt, J = 10.8, 3.8 Hz, 1H), 4.25 – 
4.14 (m, 1H), 4.06 – 3.98 (m, 1H), 3.92 – 3.84 (m, 1H), 3.80 – 3.71 (m, 6H), 3.47 – 3.23 
(m, 2H), 2.92 – 2.83 (m, 2H), 2.77 – 2.66 (m, 2H), 2.31 – 2.20 (m, 4H), 2.19 – 2.06 (m, 
2H), 1.92 – 1.66 (m, 3H), 1.63 – 1.53 (m, 6H), 1.42 (d, J = 3.7 Hz, 2H), 1.36 (s, 6H), 1.10 
– 0.94 (m, 50H), 0.91 – 0.81 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 171.04, 171.01, 
170.93, 170.92, 162.00, 159.38, 150.79, 136.92, 136.91, 135.45, 131.30, 131.28, 129.29, 
129.28, 128.46 (2C), 128.42 (2C), 126.09, 125.95, 125.93, 115.24, 81.03, 81.01, 79.95, 
79.67, 75.03, 75.00, 74.98, 72.17, 70.38, 70.31, 69.52, 69.49, 59.95, 59.91, 55.69, 55.67, 
46.13, 45.93, 44.86, 44.66, 35.27, 35.25, 34.64, 32.63, 32.59, 32.58, 31.95, 28.32, 27.38, 
27.37, 27.36, 27.28, 27.27, 27.20, 26.89, 25.26, 18.05 (12C), 11.88 (3C), 11.87 (3C); 
HRMS (ESI+) m/z calcd for C79H120Cl4N3O19Si2 [M + H] 1610.6809, found: 1610.6831. 
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(2S,3R,4R,5R)-2-((1S,2S)-3-amino-2-((3-((tert-butoxycarbonyl)amino)propyl)amino)-
1-((3aR,4R,6R,6aR)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-
dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-3-oxopropoxy)-5-(((tert-
butoxycarbonyl)amino)methyl)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (S4). To a stirred suspension of S1 (0.11 g, 0.065 
mmol) and NaHCO3 (55 mg, 0.65 mmol) in CH2Cl2 (1.3 mL) was added Pb(OAc)4 (58 
mg, 0.13 mmol) at 0 oC. The reaction mixture was stirred for 2 h at 0 oC and quenched 
with saturated aq NaHCO3, and extracted with EtOAc. The combined organic extracts 
were dried over Na2SO4 and concentrated in vacuo. The crude mixture of aldehyde S2 
was used for the next reaction without purification. To a stirred solution of S2 (97 mg, 
0.065 mmol) and N-Boc-1,3-propanediamine (46 L, 0.26 mmol) in CH2Cl2 (1.3 mL) 
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was added MS3A (0.21 g) followed by Ti(OiPr)4 (0.19 mL, 0.65 mmol). After 9 h, the 
reaction was added TMSCN (82 L, 0.65 mmol) and stirred for 12 h at rt. After 
completion, the reaction mixture was quenched with saturated aq NaHCO3, and extracted 
with EtOAc. The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. The crude mixture was passed through a silica gel pad (hexanes/EtOAc 75:25 to 
60:40) to afford the crude mixture of S3. This mixture was used for next reaction without 
further purification. To a stirred solution of S3 (0.11 g, 0.065 mmol) in EtOH/H2O (9:1, 
0.65 mL) were added HgCl2 (36 mg, 0.13 mmol) and acetaldoxime (40 L, 0.65 mmol) 
at rt. After being stirred for 8 h at rt, the reaction mixture was concentrated under reduced 
pressure. The residue was quenched with saturated aq NaHCO3, extracted with CHCl3. 
The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The 
crude product was purified by silica gel column chromatography (hexanes/EtOAc 50:50 
to CHCl3/MeOH 96:4) to afford S4 (57 mg, 0.034 mmol, 52% for 3 steps): TLC 
(CHCl3/MeOH 90:10) Rf = 0.50; []21D +0.193 (c = 2.26, CHCl3); IR (thin film) max = 
3364 (br), 2942, 2866, 1718, 1676, 1599, 1556, 1521, 1462, 1366, 1277, 1250, 1170, 
1099, 1070, 882 cm−1; 1H NMR (400 MHz, Chloroform-d) δ 7.57 – 7.51 (m, 1H), 7.31 (d, 
J = 1.9 Hz, 2H), 7.20 (dd, J = 8.5, 2.0 Hz, 1H), 6.86 (d, J = 3.4 Hz, 2H), 6.52 (d, J = 9.8 
Hz, 1H), 5.93 – 5.85 (m, 1H), 5.84 – 5.67 (m, 2H), 5.58 – 5.48 (m, 2H), 5.20 – 5.14 (m, 
1H), 5.08 (s, 1H), 5.01 – 4.93 (m, 1H), 4.84 – 4.70 (m, 2H), 4.42 – 4.34 (m, 1H), 4.24 (dd, 
J = 7.2, 4.3 Hz, 1H), 4.17 – 4.09 (m, 1H), 3.78 (s, 3H), 3.73 (q, J = 7.4 Hz, 4H), 3.40 
(ddd, J = 12.8, 7.7, 4.7 Hz, 1H), 3.36 – 3.20 (m, 3H), 3.20 – 3.11 (m, 1H), 2.75 – 2.66 (m, 
2H), 2.25 – 2.17 (m, 4H), 1.69 – 1.51 (m, 11H), 1.43 (s, 18H), 1.36 (s, 3H), 1.12 – 1.03 
(m, 42H), 1.02 (s, 3H), 0.96 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 162.05, 159.49, 
156.10, 150.63, 136.92, 135.35, 135.19, 133.97, 133.76, 133.71, 131.27, 131.23, 129.39, 
126.23, 126.15, 125.47, 125.36, 115.32, 115.16, 115.08, 105.71, 84.20, 80.93, 80.81, 
79.37, 59.98, 59.92, 55.70, 46.14, 45.96, 44.81, 32.57, 32.50, 28.44 (6C), 27.25 (4C), 
27.09, 25.23, 18.06 (12C), 11.92 (3C), 11.90 (3C); HRMS (ESI+) m/z calcd for 
C79H127Cl4N6O20Si2 [M + H] 1675.7398, found: 1675.7413. 
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(2S,3S)-3-(((2S,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxytetrahydrofuran-2-yl)oxy)-
2-((3-aminopropyl)amino)-3-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-
3,4-dihydroxytetrahydrofuran-2-yl)propanoic acid (3). To a stirred solution of S4 (57 
mg, 0.034 mmol) in CH2Cl2 (2.0 mL) was added TFA (1.0 mL). The reaction mixture 
was stirred for 2 h at rt, and all volatile were evaporated in vacuo. To a stirred solution of 
the crude mixture in H2O (1.0 mL) was added TFA (1.5 mL). The reaction mixture was 
stirred for 20 h at 50 oC, and all volatile were evaporated in vacuo. The crude mixture 
was purified by DOWEX (50W x 4) ion exchange resin. The resin was washed with 
MeOH/H2O (4:1) and MeOH. The crude product (TFA salt) was dissolved in MeOH (10 
mL) and absorbed on DOWEX (50W x 4): the crude 3 was not detected by TLC 
(CHCl3/MeOH/H2O/50% aq ammonia 56:42:7:3). The resins were washed with MeOH 
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and eluted with MeOH/50% aq ammonia (10:1). The eluate was concentrated under 
reduced pressure and the resultant aqueous solution was lyophilize to afford 3 (5.7 mg, 
6.4 mol, 100%): TLC (n-butanol/ethanol/CHCl3/28% aq ammonia 4:7:2:7) Rf = 0.10; 1H 
NMR (400 MHz, D2O) δ 7.78 (d, J = 8.1 Hz, 1H), 5.89 (d, J = 7.8 Hz, 1H), 5.78 (d, J = 
3.1 Hz, 1H), 5.22 (s, 1H), 4.40 (dd, J = 5.5, 3.2 Hz, 1H), 4.29 (t, J = 6.3 Hz, 1H), 4.22 (dd, 
J = 6.8, 5.1 Hz, 1H), 4.18 (t, J = 4.5 Hz, 1H), 4.16 – 4.08 (m, 3H), 3.59 (d, J = 3.8 Hz, 
1H), 3.28 (d, J = 12.6 Hz, 1H), 3.11 – 3.02 (m, 3H), 2.77 (dt, J = 12.8, 6.8 Hz, 1H), 2.64 
(dt, J = 12.7, 7.0 Hz, 1H), 1.83 (quin, J = 7.1 Hz, 2H); 13C NMR (101 MHz, D2O) δ 
172.95, 142.29, 108.25, 102.37, 89.42, 82.51, 79.03, 75.48, 74.44, 71.66, 71.52, 69.34, 
66.57, 52.54, 42.50, 38.04, 37.12, 24.18; HRMS (ESI+) m/z calcd for C19H32N5O11 [M + 
H] 506.2098, found: 506.2113. 
 
 
 
Synthesis of authentic sample of 7. 
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(2S,3R,4R,5R)-2-((1S,2S)-3-amino-2-((3-((benzyloxycarbonyl)amino)propyl)amino)-
1-((3aR,4R,6R,6aR)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-
dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-3-oxopropoxy)-5-(((tert-
butoxycarbonyl)amino)methyl)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (S6). To a stirred suspension of S1 (0.11 g, 0.067 
mmol) and NaHCO3 (56 mg, 0.67 mmol) in CH2Cl2 (1.3 mL) was added Pb(OAc)4 (59 
mg, 0.13 mmol) at 0 oC. The reaction mixture was stirred for 2 h at 0 oC and quenched 
with saturated aq NaHCO3, and extracted with EtOAc. The combined organic extracts 
were dried over Na2SO4 and concentrated in vacuo. The crude mixture of aldehyde S2 
was used for the next reaction without purification. To a stirred solution of S2 (99 mg, 
0.067 mmol) and N-Cbz-1,3-propanediamine (56 mg, 0.27 mmol) in CH2Cl2 (1.3 mL) 
was added MS3A (0.22 g) followed by Ti(OiPr)4 (0.20 mL, 0.67 mmol). After 10 h, the 
reaction was added TMSCN (84 L, 0.67 mmol) and stirred for 7 h at rt. After 
completion, the reaction mixture was quenched with saturated aq NaHCO3, and extracted 
with EtOAc. The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. The crude mixture was passed through a silica gel pad (hexanes/EtOAc 75:25 to 
60:40) to afford the crude mixture of S3. This mixture was used for next reaction without 
further purification. To a stirred solution of S5 (0.11 g, 0.067 mmol) in EtOH/H2O (9:1, 
0.67 mL) were added HgCl2 (36 mg, 0.13 mmol) and acetaldoxime (41 L, 0.67 mmol) 
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at rt. After being stirred for 15 h at rt, the reaction mixture was concentrated under 
reduced pressure. The residue was quenched with saturated aq NaHCO3, extracted with 
CHCl3. The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. The crude product was purified by silica gel column chromatography 
(hexanes/EtOAc 50:50 to CHCl3/MeOH 96:4) to afford S6 (55 mg, 0.032 mmol, 48% for 
3 steps): TLC (CHCl3/MeOH 90:10) Rf = 0.50; []20D +0.116 (c = 0.70, CHCl3); IR (thin 
film) max = 3348 (br), 2941, 2866, 1718, 1675, 1600, 1555, 1526, 1457, 1367, 1276, 
1249, 1218, 1159, 1100, 1070, 1049, 882 cm−1; 1H NMR (400 MHz, Chloroform-d) δ 
7.52 (d, J = 8.3 Hz, 1H), 7.37 – 7.29 (m, 6H), 7.22 – 7.16 (m, 2H), 6.86 (d, J = 2.6 Hz, 
2H), 6.51 (d, J = 13.7 Hz, 1H), 6.01 – 5.88 (m, 1H), 5.83 – 5.63 (m, 3H), 5.60 – 5.45 (m, 
3H), 5.20 – 4.92 (m, 6H), 4.84 – 4.73 (m, 2H), 4.36 – 4.07 (m, 3H), 3.79 – 3.69 (m, 7H), 
3.44 – 3.15 (m, 4H), 2.76 – 2.63 (m, 2H), 2.34 – 2.15 (m, 5H), 1.76 – 1.46 (m, 6H), 1.41 
(s, 9H), 1.36 – 1.23 (m, 4H), 1.12 – 0.99 (m, 46H), 0.96 (d, J = 6.6 Hz, 6H); 13C NMR 
(101 MHz, CDCl3) δ 170.91, 162.04, 159.45, 156.58, 156.05, 150.66, 136.86, 136.83, 
136.50, 135.08, 133.95, 133.72, 131.24, 131.18, 129.36, 128.63, 128.47 (2C), 128.09 
(2C), 126.21, 126.15, 125.35, 125.24, 115.28, 115.10, 105.87, 84.11, 79.41, 74.59, 66.64, 
59.93, 59.88, 55.68, 46.10, 45.91, 44.77, 32.56, 32.54, 32.49, 28.43, 27.22 (3C), 27.02, 
25.12, 18.03 (12C), 11.86 (3C), 11.85 (3C); HRMS (ESI+) m/z calcd for 
C82H125Cl4N6O20Si2 [M + H] 1709.7241, found: 1709.7260. 
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tert-Butyl (((2R,3S,4R,5S)-5-((1S,2S)-3-amino-2-((3-aminopropyl)amino)-1-((2S,5R)-
5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-3-
oxopropoxy)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)carbamate (7). To a stirred 
solution of S6 (9.4 mg, 5.5 mol) in CH2Cl2 (2.0 mL) was added TFA (1.0 mL). The 
reaction mixture was stirred for 2 h at rt, and all volatile were evaporated in vacuo. To a 
stirred solution of the crude mixture in H2O (0.2 mL) was added TFA (0.8 mL). The 
reaction mixture was stirred for 2 h at rt, and all volatile were evaporated in vacuo. To a 
stirred solution of the crude mixture in THF-H2O (1:1, 0.5 mL) were added NaHCO3 (8.6 
mg, 0.10 mmol) and Boc2O (6.7 mg, 0.031 mmol). The reaction mixture was stirred for 2 
h at rt, and all volatile were evaporated in vacuo. The crude mixture was passed through a 
silica gel pad (EtOAc to CHCl3/MeOH/H2O/28% aq ammonia 56:42:7:3) to afford the 
crude mixture of S7. To a stirred solution of the crude mixture of S7 in IPA-H2O-HCO2H 
(100:10:1, 1.0 mL) was added Pd/C (10 wt % 6.8 mg). H2 gas was introduced and the 
reaction mixture was stirred for 1 h under H2. The solution was filtered through Celite 
and concentrated in vacuo. The crude mixture was purified by C18 reverse-phase HPLC 
[column: Luna® (100 Å, 10 m, 250 x 10 mm), solvents: 25:75 MeOH:0.05 M 
NH4HCO3 in H2O, flow rate: 3.0 mL/min, UV: 254 nm] to afford 7 (2.7 mg, 4.42 mol, 
81%, retention time: 13.0 min): TLC (CHCl3/MeOH/H2O/28% aq ammonia 56:42:7:3) Rf 
= 0.10; IR (thin film) max = 3329 (br), 3312 (br), 2979, 2929, 1678, 1572, 1508, 1459, 
1392, 1367, 1279, 1131, 1115, 1077, 1057, 1018 cm−1; 1H NMR (400 MHz, Deuterium 
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Oxide) δ 7.76 (d, J = 7.8 Hz, 1H), 5.79 (s, 1H), 5.76 (d, J = 7.8 Hz, 1H), 5.05 (s, 1H), 
4.25 – 4.13 (m, 3H), 4.03 (dd, J = 10.5, 6.8 Hz, 3H), 3.52 (d, J = 6.4 Hz, 1H), 3.36 – 3.31 
(m, 2H), 3.29 (s, 1H), 2.97 (t, J = 7.3 Hz, 2H), 2.65 (t, J = 7.1 Hz, 2H), 1.82 – 1.73 (m, 
2H), 1.34 (s, 9H); 13C NMR (101 MHz, D2O) δ 176.10, 161.92, 161.73, 160.96, 146.67, 
140.44, 109.60, 102.04, 90.59, 90.39, 82.37, 81.77, 80.86, 79.92, 75.26, 74.88, 41.07, 
38.32, 38.19, 27.69 (3C); HRMS (ESI+) m/z calcd for C24H41N6O12 [M + H] 605.2782, 
found: 605.2795. 
 
 
 
Synthesis of authentic sample of 8. 
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tert-Butyl (((2R,3S,4R,5S)-5-((1S,2S)-3-amino-2-((3-((tert-
butoxycarbonyl)amino)propyl)amino)-1-((2S,5R)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-3-oxopropoxy)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)carbamate (8). To a stirred solution of 4 (4.1 
mg, 8.1 mol) and NaHCO3 (6.8 mg, 0.081 mmol) in THF-H2O (1:1, 0.2 mL) was added 
Boc2O (8.9 mg, 0.041 mmol). The reaction mixture was stirred for 12 h at rt, and all 
volatile were evaporated in vacuo. The crude mixture was passed through a silica gel 
column chromatography (EtOAc to CHCl3/MeOH/H2O/28% aq ammonia 56:42:7:3) to 
afford 8 (5.0 mg, 7.2 mol, 88%): TLC (CHCl3/MeOH/H2O/28% aq ammonia 56:42:7:3) 
Rf = 0.55; []21D +0.558 (c = 0.45, methanol); IR (thin film) max = 3331 (br), 2976, 2932, 
1681, 1517, 1456, 1392, 1366, 1276, 1253, 1167, 1131, 1112, 1086, 1013 cm−1; 1H NMR 
(400 MHz, Methanol-d4) δ 7.95 (d, J = 8.1 Hz, 1H), 5.83 (s, 1H), 5.76 (d, J = 8.2 Hz, 1H), 
5.09 (s, 1H), 4.19 – 4.14 (m, 4H), 4.04 (d, J = 6.4 Hz, 1H), 4.00 – 3.93 (m, 4H), 3.45 (d, J 
= 6.3 Hz, 1H), 3.12 (t, J = 6.8 Hz, 2H), 2.62 (q, J = 6.0, 5.6 Hz, 2H), 1.69 – 1.63 (m, 2H), 
1.45 (s, 9H), 1.43 (s, 9H); 13C NMR (101 MHz, MeOD) δ 166.19, 158.56, 152.19, 142.31, 
110.64, 102.63, 91.56, 85.12, 83.90, 80.75, 80.30, 79.90, 76.69, 75.55, 72.89, 71.12, 
65.24, 46.58, 43.79, 39.24, 31.10, 28.91 (3C), 28.82 (3C); HRMS (ESI+) m/z calcd for 
C29H49N6O14 [M + H] 705.3307, found: 705.3324. 
 
 
 
Selective Boc protection of 4. 
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tert-Butyl (((2R,3S,4R,5S)-5-((1S,2S)-3-amino-2-((3-aminopropyl)amino)-1-((2S,5R)-
5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-3-
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oxopropoxy)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)carbamate (7). To a stirred 
solution of 4 (8.1 mg, 0.016 mmol), Cu(OAc)2 (1.0 M in H2O, 0.048 mL, 0.048 mmol), 
and NaOH (1.0 M in H2O, 0.048 mL, 0.048 mmol) in H2O-MeOH-DMF (1:1:1, 0.6 mL) 
was added Boc2O (8.7 mg, 0.040 mmol). The reaction mixture was stirred for 4 h at rt, 
filtered and concentrated in vacuo. The crude mixture was purified by C18 reverse-phase 
HPLC [column: Luna® (100 Å, 10 m, 250 x 10 mm), solvents: 25:75 MeOH:0.05 M 
NH4HCO3 in H2O, flow rate: 3.0 mL/min, UV: 254 nm] to afford 4 (8.8 mg, 0.015 mmol, 
91%, retention time: 13.0 min): TLC (CHCl3/MeOH/H2O/28% aq ammonia 56:42:7:3) Rf 
= 0.10; IR (thin film) max = 3329 (br), 3312 (br), 2979, 2929, 1678, 1572, 1508, 1459, 
1392, 1367, 1279, 1131, 1115, 1077, 1057, 1018 cm−1; 1H NMR (400 MHz, Deuterium 
Oxide) δ 7.76 (d, J = 7.8 Hz, 1H), 5.79 (s, 1H), 5.76 (d, J = 7.8 Hz, 1H), 5.05 (s, 1H), 
4.25 – 4.13 (m, 3H), 4.03 (dd, J = 10.5, 6.8 Hz, 3H), 3.52 (d, J = 6.4 Hz, 1H), 3.36 – 3.31 
(m, 2H), 3.29 (s, 1H), 2.97 (t, J = 7.3 Hz, 2H), 2.65 (t, J = 7.1 Hz, 2H), 1.82 – 1.73 (m, 
2H), 1.34 (s, 9H); 13C NMR (101 MHz, D2O) δ 176.10, 161.92, 161.73, 160.96, 146.67, 
140.44, 109.60, 102.04, 90.59, 90.39, 82.37, 81.77, 80.86, 79.92, 75.26, 74.88, 41.07, 
38.32, 38.19, 27.69 (3C); HRMS (ESI+) m/z calcd for C24H41N6O12 [M + H] 605.2782, 
found: 605.2795. 
 
 
 
Selective Cbz protection of 4. 
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Benzyl (((2R,3S,4R,5S)-5-((1S,2S)-3-amino-2-((3-aminopropyl)amino)-1-((2S,5R)-5-
(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-3-
oxopropoxy)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)carbamate (9). To a stirred 
solution of 4 (4.7 mg, 9.3 mol), Cu(OAc)2 (1.0 M in H2O, 0.028 mL, 0.028 mmol), and 
NaOH (1.0 M in H2O, 0.028 mL, 0.028 mmol) in H2O-MeOH-DMF (1:1:1, 0.3 mL) was 
added CbzOSu (5.7 mg, 0.023 mmol) or CbzCl (3.3 L, 0.023 mmol). The reaction 
mixture was stirred for 7 h at rt, filtered and concentrated in vacuo. The crude mixture 
was purified by C18 reverse-phase HPLC [column: Luna® (100 Å, 10 m, 250 x 10 mm), 
solvents: 35:65 MeOH:0.05 M NH4HCO3 in H2O, flow rate: 3.0 mL/min, UV: 254 nm] to 
afford 9 (5.5 mg, 8.7 mol, 93%, retention time: 10.2 min): TLC (n-
butanol/ethanol/CHCl3/28% aq ammonia 4:7:2:7) Rf = 0.55; []20D +0.122 (c = 0.26, 
methanol); IR (thin film) max = 3330 (br), 3125, 3037, 2958, 2925, 2852, 2808, 1686, 
1677, 1542, 1443, 1399, 1268, 1114, 1057 cm−1; 1H NMR (400 MHz, Methanol-d4) δ 
7.94 (d, J = 8.1 Hz, 1H), 7.36 – 7.28 (m, 5H), 5.82 (d, J = 2.1 Hz, 1H), 5.75 (d, J = 8.1 
Hz, 1H), 5.08 (s, 1H), 5.06 (s, 2H), 4.17 – 4.14 (m, 4H), 4.04 (dd, J = 6.6, 2.4 Hz, 1H), 
3.97 – 3.94 (m, 4H), 3.44 (d, J = 6.3 Hz, 1H), 3.21 (t, J = 6.7 Hz, 2H), 2.67 – 2.59 (m, 
2H), 1.69 (quin, J = 7.0 Hz, 2H); 13C NMR (101 MHz, MeOD) δ 166.23, 158.96, 158.55, 
152.22, 142.32, 138.46, 129.47 (2C), 128.82 (2C), 110.64, 102.59, 91.58, 85.19, 83.87, 
80.79, 80.31, 76.70, 75.56, 72.90, 71.15, 67.38, 65.27, 46.47, 43.81, 39.70, 31.02; HRMS 
(ESI+) m/z calcd for C27H39N6O12 [M + H] 639.2626, found: 639.2641. 
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Synthesis of APPU (2) from 7. 
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tert-Butyl (((2R,3S,4R,5S)-5-((1S,2S)-3-amino-1-((2S,5R)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-3-oxo-2-((3-(3-(4-
(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-
yl)benzyl)ureido)propyl)amino)propoxy)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl)carbamate (14). To a stirred solution of 7 (4.3 mg, 7.1 mol, prepared from 
S7) and 13 (9.8 mg, 0.021 mmol) in DMF-CH2Cl2 (1:1, 0.2 mL) was added Et3N (4.7 L, 
0.036 mmol) at rt. The reaction mixture was stirred for 12 h at rt, and all volatile were 
evaporated in vacuo. The crude mixture was passed through a silica gel column 
chromatography (EtOAc to CHCl3/MeOH/H2O/28% aq ammonia 56:42:7:3) to afford 14 
(6.4 mg, 6.4 mol, 90%). The 1H NMR spectral data was confirmed to be identical by 
comparison with 14 prepared via newly developed selective protection strategy: TLC 
(CHCl3/MeOH/H2O/28% aq ammonia 56:42:7:3) Rf = 0.55; []21D +0.086 (c = 0.17, 
methanol); IR (thin film) max = 3325 (br), 2930, 2855, 1678, 1553, 1505, 1267, 1242, 
1197, 1163, 1113, 1033 cm−1; 1H NMR (400 MHz, Methanol-d4) δ 7.92 (d, J = 8.0 Hz, 
1H), 7.21 – 7.16 (m, 4H), 7.01 – 6.95 (m, 6H), 5.82 (s, 1H), 5.75 (d, J = 8.1 Hz, 1H), 5.10 
(s, 1H), 4.53 (dd, J = 7.8, 4.0 Hz, 2H), 4.34 (s, 1H), 4.26 (s, 2H), 4.22 (s, 1H), 4.19 – 4.15 
(m, 2H), 4.06 (d, J = 4.5 Hz, 1H), 3.98 – 3.94 (m, 2H), 3.93 (s, 1H), 3.52 – 3.44 (m, 4H), 
3.26 – 3.20 (m, 1H), 3.08 (ddd, J = 12.2, 8.6, 3.1 Hz, 4H), 2.15 – 2.06 (m, 2H), 1.91 – 
1.82 (m, 2H), 1.44 (s, 9H); 13C NMR (101 MHz, MeOD) δ 173.09, 172.96, 158.76, 
157.79, 157.63, 152.17, 152.09, 131.12, 130.54 (2C), 130.43, 129.63 (2C), 129.23, 
123.85, 123.58, 121.89, 120.53, 120.32, 118.20, 118.11 (2C), 118.02, 117.15 (2C), 76.68, 
74.01, 73.34, 71.10, 43.80, 31.62, 31.49, 28.89 (3C), 28.75, 23.77, 22.54; HRMS (ESI+) 
m/z calcd for C44H60F3N8O15 [M + H] 997.4130, found: 997.4168. 
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Figure S2: 1H-NMR comparison between 14 synthesized from S7 in two steps 
(debenzylation and coupling with 13) and 14 synthesized via a new method described in this 
manuscript 
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(2S,3S)-3-(((2S,3R,4S,5R)-5-(Aminomethyl)-3,4-dihydroxytetrahydrofuran-2-
yl)oxy)-3-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)-2-((3-(3-(4-(4-(4-
(trifluoromethoxy)phenoxy)piperidin-1-
yl)benzyl)ureido)propyl)amino)propanamide (2). To a stirred solution of 14 (6.4 mg, 
6.4 mol) in CH2Cl2 (0.35 mL) was added TFA (0.15 mL). The reaction mixture was 
stirred for 3 h at rt, and all volatile were evaporated in vacuo. The crude mixture was 
purified by DOWEX (50W x 4) ion exchange resin. The resin was washed with 
MeOH/H2O (4:1) and MeOH. The crude product (TFA salt) was dissolved in MeOH (10 
mL) and absorbed on DOWEX (50W x 4): the crude 2 was not detected by TLC 
(CHCl3/MeOH/H2O/50% aq ammonia 56:42:7:3). The resins were washed with MeOH 
and eluted with MeOH/50% aq ammonia (10:1). The eluate was concentrated under 
reduced pressure and the resultant aqueous solution was lyophilize to afford 2 (5.7 mg, 
6.4 mol, 100%): TLC (CHCl3/MeOH/H2O/28% aq ammonia 56:42:7:3) Rf = 0.35; 
[]20D +0.037 (c = 0.05, methanol); IR (thin film) max = 3310 (br), 3077, 2928, 2853, 
1649, 1614, 1555, 1515, 1504, 1267, 1241, 1222, 1196, 1162, 1112, 1037, 1029 cm−1; 1H 
NMR (400 MHz, Methanol-d4) δ 7.84 (d, J = 8.1 Hz, 1H), 7.22 – 7.15 (m, 4H), 7.06 – 
6.96 (m, 6H), 5.79 (s, 1H), 5.74 (d, J = 8.1 Hz, 1H), 5.13 (s, 1H), 4.58 – 4.51 (m, 2H), 
4.26 (s, 1H), 4.23 – 4.20 (m, 1H), 4.19 – 4.14 (m, 2H), 4.10 (d, J = 4.4 Hz, 1H), 3.97 – 
3.94 (m, 1H), 3.47 (d, J = 10.7 Hz, 2H), 3.40 (d, J = 5.0 Hz, 1H), 3.23 (t, J = 6.7 Hz, 2H), 
3.07 (ddd, J = 12.5, 8.5, 3.6 Hz, 2H), 2.90 (dd, J = 13.3, 3.8 Hz, 1H), 2.80 (dd, J = 13.3, 
7.2 Hz, 1H), 2.70 – 2.55 (m, 2H), 2.17 – 2.05 (m, 2H), 1.92 – 1.82 (m, 2H), 1.69 – 1.60 
(m, 2H); 13C NMR (101 MHz, MeOD) δ 158.76, 157.63, 152.09, 143.91, 131.12, 130.54 
(2C), 130.43, 129.63 (2C), 129.24, 123.85, 123.59, 121.89, 120.53, 120.32, 118.19, 
118.11 (2C), 118.03, 117.16 (2C), 102.63, 76.69, 74.01, 73.35, 43.80, 31.62, 31.49, 28.92, 
22.53; HRMS (ESI+) m/z calcd for C39H52F3N8O13 [M + H] 897.3606, found: 897.3629. 
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Figure S3: 1H-NMR comparison of 2 with the authentic sample prepared via the previously 
reported method1 
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Figure S4: HPLC analysis of APPU (2) 
Conditions: column: Phenomenex Luna® 10 m C18 100 Å 250 x 10 mm column, 
solvents: 65:35 MeOH:0.05 M NH4HCO3 in water, flow rate: 3.0 mL/min, UV: 254 nm 
 
 
 
NMR analyses of Cu complex. 
 
A stirred solution of 1:1:1 mixture of 11 (5.2 mg, 0.025 mmol), 12 (6.4 mg, 0.025 mmol) 
and CuCl2 (1.0 M in H2O, 0.028 mL, 0.028 mmol) in H2O-MeOH (1:1, 0.2 mL) was added 
NaOH (1.0 M in H2O, 0.025 mL, 0.025 mmol). After 30 min, all volatiles were lyophilized. 
The crude mixture was dissolved in D2O (0.5 mL). 
 
Table S1: 1H-NMR Chemical shifts for the Cu-complexes with 11 and 12 
 
OH2N
STol
HO OH
11
12
++ CuCl2
H
NH2N
H2N O
21'
2'
3'
1
23
4
5
 
 
 
 H-2 H-1’ H-2’ H-3’ 
11 4.30 2.56 1.77 2.92 
+Cu 5.03 3.06, ~3 2.03 2.97 
 +0.73 +0.50, ~+0.5 +0.26 +0.05 
 
 H-1 H-2 H-3 H-4 H-5 
12 5.25 3.89 4.11 4.05 3.18, 2.83 
+Cu 5.25 3.89 4.11 4.05 3.18, 2.83 
 0 0 0 0 0 
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Cytotoxicity Assays 
 
Selected molecules were tested for cytotoxicity (IC50) in cancer and healthy cells via a 
MTT colorimetric assay.  
For Vero cells:  Vero cell was cultured in Complete eagle`s minimum essential growth 
medium (EMEM) containing L-glutamine, sodium pyruvate, minimum essential amino 
acids, penicillin-streptomycin and 10% fetal bovine serum. Inoculating number of cells 
were 400,000 cells/mL and a final 40,000 cells/well. After 72 h of exposure of molecules 
to this cell line at concentrations ranging from 0.78 to 200 g/mL, the culture medium 
was changed to complete EMEM without phenol red before addition of yellow 
tetrazolium dye; MTT. Viability was assessed on the basis of cellular conversion of MTT 
into a purple formazan product. The absorbance of the colored formazan product was 
measured at 570 nm by BioTek Synergy HT Spectrophotometer. Linearity of the MTT 
response to the cell number was determined. 
Each cell was cultured in recommended medium by ATCC.  
 
 
 
Figure S5: MTT response vs population of Vero cells 
 
 
 
Table S2: Cytotoxicity of APPB and APPU against representative cell lines 
 
Cells          /      Molecule APPB (IC50 M) APPU (IC50 M) 
Panc-1 <0.098 0.098 
AsPC-1 0.098 0.098 
Vero 35-65 12.5-55 
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